Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors

INTRODUCTION: Only a few reports have determined whether recently advanced anticancer drugs, particularly next-generation tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), prolong the survival of patients with NSCLC in the real world. METHODS: To evaluate the association bet...

Descripción completa

Detalles Bibliográficos
Autores principales: Ariyasu, Ryo, Kakuto, Sho, Miyadera, Keiki, Akita, Takahiro, Kiritani, Ayu, Tsugitomi, Ryosuke, Amino, Yoshiaki, Uchibori, Ken, Kitazono, Satoru, Yanagitani, Noriko, Nishio, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329142/
https://www.ncbi.nlm.nih.gov/pubmed/37426307
http://dx.doi.org/10.1016/j.jtocrr.2023.100524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329142/
https://www.ncbi.nlm.nih.gov/pubmed/37426307
http://dx.doi.org/10.1016/j.jtocrr.2023.100524

Ejemplares similares